Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

INTRODUCTION: Clinical remission in patients with ankylosing spondylitis (AS) has been determined using composite indices such as the AS Disease Activity Score inactive disease (ASDAS-ID), Assessment of SpondyloArthritis international Society criteria partial remission (ASAS-PR), and low Bath AS Dis...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Rheumatol Ther
Auteurs principaux: Baraliakos, Xenofon, Van den Bosch, Filip, Machado, Pedro M., Gensler, Lianne S., Marzo-Ortega, Helena, Sherif, Bintu, Quebe-Fehling, Erhard, Porter, Brian, Gaillez, Corine, Deodhar, Atul
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2020
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7991028/
https://ncbi.nlm.nih.gov/pubmed/33351179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-020-00269-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires